Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

particular, should our royalties received from BSC or our product sales decline significantly in future periods, our liquidity may be adversely affected, and we may be forced to explore alternative funding sources through debt, equity or other public or private securities offerings, or to pursue certain reorganization, restructuring or other strategic alternatives. There can be no assurance that if we pursue such financing activities that alternative sources of funding would be available to us on attractive terms, if at all. In addition, we may not be able to complete any restructuring, reorganization or strategic activities on terms that would be favorable for us or our shareholders. Capital markets conditions have deteriorated significantly during 2008 and 2009, including a significant and material decline in the level of corporate lending activity, combined with a significant increase in the cost of any such lending. Current market conditions may have a material impact on our ability to secure any alternative source of funding, our ability to secure interim financing or to complete any of the activities as described on favorable terms, if at all.

    Financial Information
    ---------------------

This press release contains the condensed financial statements derived from the unaudited interim consolidated financial statements for the quarter ended March 31, 2009. Full unaudited interim consolidated financial statements and Management's Discussion and Analysis for the quarter ended March 31, 2009 will be filed on Form 10-Q on or before May 15, 2009.

Amounts, unless specified otherwise, are expressed in U.S. dollars. Financial results are reported under U.S. GAAP unless otherwise noted. All per share amounts are stated on a diluted basis unless otherwise noted.

    Use of Certain Non-GAAP Financial Measures
    ------------------------------------------

Certain financial
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. Using a bio-mimicking analog of one ... grass, an international research team led by Alejandro ... taken a major step in developing long-sought polymer ... electricity for use in electronic devices. , ... Amherst and others at Stanford University and Dresden ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the ... precise tool for measuring displacement in rubber and ... maximum movement distance, the DSES-1000 can measure elongations ... of 10 mm. In addition, it achieves +/- ... and within +/- 100 µm below 50-mm stroke. ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... (Amex: PLX ), announced today the pricing of ... stock at a,public offering price of $5.00 per share. ... to purchase up to 1,500,000 additional shares of,common stock ... is acting as sole book-running manager for this,offering. CIBC ...
... Oct. 24 , First Quarter Highlights:, - ... - Diluted EPS up 40% to $0.35 year-over-year, excluding ... related to one-time non-U.S. net tax adjustments PAREXEL ... results for the first quarter ended September 30, 2007. ...
... The Pittsburgh Life Sciences,Greenhouse (PLSG), the private/public ... a fast track for growth, announced that ... LLC, a developmental-stage,medical device company, whose goal ... probe that will alleviate the existing,limitations of ...
Cached Biology Technology:Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 9The PLSG Invests $115,000 in Innovention Technologies, LLC 2
(Date:9/30/2014)... -- Pollution in urban and farm runoff in Hawaii ... study finds. , The study, published Tuesday in ... nitrogen in the runoff ends up in algae that ... the animals, eyes, flippers and internal organs. , Scientists ... National Oceanic and Atmospheric Administration (NOAA) conducted the study ...
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... Here,s some hope: A new research report published in ... , explains how scientists developed a synthetic version ... embryo development in human and mouse eggs similar to ... cell during fertilization. , "We believe that the results ... our understanding of human fertilization by providing a precise ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... LANE, OKCorn gluten meal, a powdery byproduct of ... for use as an organic, non-selective preemergence or preplant-incorporated ... of Agriculture-Agricultural Research Service and Oklahoma State University recently ... applications on direct-seeded squash (Cucurbita pepo), and determined that ...
... entomologists will meet at the Hilton Waikoloa Village March 27-30, ... Region," the theme of this year,s Annual Meeting of the ... Each year, invasive species such as the coffee berry borer ... to Hawaiian crops. Members of the media are invited to ...
... cancer cells trigger a set of genes similar to those ... Research in Biomedicine (IRB Barcelona) have found. The team of ... with colorectal cancer undergo genetic tests of their intestinal epithelium ... results of the study, published online this week in ...
Cached Biology News:Corn gluten meal tested on squash survival, yields 2Insect scientists battle invasive species in Hawaii 2Stem cells may be key to understanding the origins of colon cancer and detecting relapse 2
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
Biology Products: